【正文】
16740742(2017)11(c)014003 [Abstract] Objective This paper tries to investigate the clinical effect of rebinant human interferon α2b vaginal effervescence tablet in the treatment of high risk human papillomavirus (HPV) infection. Methods 115 cases of cervical highrisk HPV infection patients from June 2016 to April 2017 were convenient selected and divided into the experimental group (rebinant human interferon α2b vaginal effervescent tablets, 58 cases) and the control group (regular followup, 57 cases), after the treatment, the HPV negative rate and adverse reaction of the two groups were pared. Results The total negative rate of HPV in the experimental group was %, significantly higher than that in the control group of %, the difference was statistically significant(P), the patients had no obvious disfort, and the adverse reaction rate was %. Conclusion Rebinant human interferon α2b vaginal effervescent tablets in the treatment of cervical highrisk HPV infection has good curative effect and no ob